Kestra Medical Technologies (NASDAQ:KMTS) Reaches New 1-Year High - Should You Buy?

Key Points

• Kestra shares hit a 52-week high of $31.10, up 8.2% on the day, and last traded at $30.88.
• Analysts have a “Moderate Buy” consensus, but their average $29 price target is below the stock’s latest trading price; ratings include five Buys, two Holds, and one Sell.
• The company reported a quarterly loss of $0.75 per share, missing estimates of a $0.61 loss, on revenue of $30.97 million. Insiders sold 289,551 shares worth about $8.2 million over the last quarter.

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report)'s share price reached a new 52-week high during mid-day trading on Wednesday. The stock traded as high as $31.10 and last traded at $30.8840, with a volume of 86,422 shares changing hands. The stock had previously closed at $29.01.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on KMTS. Wolfe Research set a $30.00 price objective on shares of Kestra Medical Technologies in a research note on Wednesday, July 15th. Piper Sandler reissued an "overweight" rating on shares of Kestra Medical Technologies in a research report on Tuesday, September 15th. Evercore assumed coverage on shares of Kestra Medical Technologies in a research note on Tuesday, October 20th. They set an "outperform" rating and a $34.00 price target for the company. Oppenheimer initiated coverage on Kestra Medical Technologies in a report on Tuesday, July 21st. They set a "market perform" rating for the company. Finally, Royal Bank Of Canada set a $30.00 price target on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Kestra Medical Technologies has an average rating of "Moderate Buy" and a consensus target price of $29.00.

Kestra Medical Technologies Trading Up 8.2%

The stock has a market capitalization of $1.87 billion, a P/E ratio of -11.70 and a beta of 0.45. The firm's 50 day moving average price is $26.79 and its 200 day moving average price is $23.90. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.69 and a quick ratio of 4.69.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last issued its quarterly earnings data on Monday, September 14th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.14). Kestra Medical Technologies had a negative net margin of 140.43% and a negative return on equity of 63.83%. The company had revenue of $30.97 million for the quarter. As a group, equities research analysts expect that Kestra Medical Technologies, Ltd. will post -2.45 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Raymond Cohen sold 3,330 shares of the stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $29.28, for a total value of $97,502.40. Following the completion of the transaction, the director directly owned 54,790 shares in the company, valued at $1,604,251.20. This trade represents a 5.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Vaseem Mahboob sold 4,788 shares of Kestra Medical Technologies stock in a transaction that occurred on Thursday, October 29th. The shares were sold at an average price of $30.60, for a total transaction of $146,512.80. Following the transaction, the chief financial officer owned 60,609 shares of the company's stock, valued at $1,854,635.40. The trade was a 7.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 289,551 shares of company stock worth $8,171,898. 5.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Kestra Medical Technologies

Several institutional investors have recently made changes to their positions in KMTS. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Kestra Medical Technologies in the 3rd quarter worth $353,000. Sterling Capital Management LLC boosted its stake in Kestra Medical Technologies by 834.0% during the third quarter. Sterling Capital Management LLC now owns 878 shares of the company's stock valued at $25,000 after buying an additional 784 shares during the last quarter. Corient Private Wealth LP increased its stake in Kestra Medical Technologies by 284.2% in the 2nd quarter. Corient Private Wealth LP now owns 60,614 shares of the company's stock worth $1,542,000 after acquiring an additional 44,839 shares during the last quarter. California State Teachers Retirement System raised its stake in Kestra Medical Technologies by 39.2% during the first quarter. California State Teachers Retirement System now owns 27,835 shares of the company's stock valued at $555,000 after purchasing an additional 7,844 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Kestra Medical Technologies by 6.6% in the 1st quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company's stock valued at $1,844,000 after acquiring an additional 5,731 shares during the last quarter.

Kestra Medical Technologies Company Profile

Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient's heart rhythm and deliver a therapeutic shock when clinically necessary.

The company's platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.